1
|
Burgert-Brucker CR, Zoerhoff KL, Headland M, Shoemaker EA, Stelmach R, Karim MJ, Batcho W, Bougouma C, Bougma R, Benjamin Didier B, Georges N, Marfo B, Lemoine JF, Pangaribuan HU, Wijayanti E, Coulibaly YI, Doumbia SS, Rimal P, Salissou AB, Bah Y, Mwingira U, Nshala A, Muheki E, Shott J, Yevstigneyeva V, Ndayishimye E, Baker M, Kraemer J, Brady M. Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis. PLoS Negl Trop Dis 2020; 14:e0008301. [PMID: 32479495 PMCID: PMC7289444 DOI: 10.1371/journal.pntd.0008301] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Revised: 06/11/2020] [Accepted: 04/16/2020] [Indexed: 11/20/2022] Open
Abstract
Achieving elimination of lymphatic filariasis (LF) as a public health problem requires a minimum of five effective rounds of mass drug administration (MDA) and demonstrating low prevalence in subsequent assessments. The first assessments recommended by the World Health Organization (WHO) are sentinel and spot-check sites—referred to as pre-transmission assessment surveys (pre-TAS)—in each implementation unit after MDA. If pre-TAS shows that prevalence in each site has been lowered to less than 1% microfilaremia or less than 2% antigenemia, the implementation unit conducts a TAS to determine whether MDA can be stopped. Failure to pass pre-TAS means that further rounds of MDA are required. This study aims to understand factors influencing pre-TAS results using existing programmatic data from 554 implementation units, of which 74 (13%) failed, in 13 countries. Secondary data analysis was completed using existing data from Bangladesh, Benin, Burkina Faso, Cameroon, Ghana, Haiti, Indonesia, Mali, Nepal, Niger, Sierra Leone, Tanzania, and Uganda. Additional covariate data were obtained from spatial raster data sets. Bivariate analysis and multilinear regression were performed to establish potential relationships between variables and the pre-TAS result. Higher baseline prevalence and lower elevation were significant in the regression model. Variables statistically significantly associated with failure (p-value ≤0.05) in the bivariate analyses included baseline prevalence at or above 5% or 10%, use of Filariasis Test Strips (FTS), primary vector of Culex, treatment with diethylcarbamazine-albendazole, higher elevation, higher population density, higher enhanced vegetation index (EVI), higher annual rainfall, and 6 or more rounds of MDA. This paper reports for the first time factors associated with pre-TAS results from a multi-country analysis. This information can help countries more effectively forecast program activities, such as the potential need for more rounds of MDA, and prioritize resources to ensure adequate coverage of all persons in areas at highest risk of failing pre-TAS. Achieving elimination of lymphatic filariasis (LF) as a public health problem requires a minimum of five rounds of mass drug administration (MDA) and being able to demonstrate low prevalence in several subsequent assessments. LF elimination programs implement sentinel and spot-check site assessments, called pre-TAS, to determine whether districts are eligible to implement more rigorous population-based surveys to determine whether MDA can be stopped or if further rounds are required. Reasons for failing pre-TAS are not well understood and have not previously been examined with data compiled from multiple countries. For this analysis, we analyzed data from routine USAID and WHO reports from Bangladesh, Benin, Burkina Faso, Cameroon, Ghana, Haiti, Indonesia, Mali, Nepal, Niger, Sierra Leone, Tanzania, and Uganda. In a model that included multiple variables, high baseline prevalence and lower elevation were significant. In models comparing only one variable to the outcome, the following were statistically significantly associated with failure: higher baseline prevalence at or above 5% or 10%, use of the FTS, primary vector of Culex, treatment with diethylcarbamazine-albendazole, lower elevation, higher population density, higher Enhanced Vegetation Index, higher annual rainfall, and six or more rounds of mass drug administration. These results can help national programs plan MDA more effectively, e.g., by focusing resources on areas with higher baseline prevalence and/or lower elevation.
Collapse
Affiliation(s)
| | - Kathryn L. Zoerhoff
- Global Health Division, RTI International, Washington, DC, United States of America
| | - Maureen Headland
- Global Health Division, RTI International, Washington, DC, United States of America
- Global Health, Population, and Nutrition, FHI 360, Washington, DC, United States of America
| | - Erica A. Shoemaker
- Global Health Division, RTI International, Washington, DC, United States of America
| | - Rachel Stelmach
- Global Health Division, RTI International, Washington, DC, United States of America
| | | | - Wilfrid Batcho
- National Control Program of Communicable Diseases, Ministry of Health, Cotonou, Benin
| | - Clarisse Bougouma
- Lymphatic Filariasis Elimination Program, Ministère de la Santé, Ouagadougou, Burkina Faso
| | - Roland Bougma
- Lymphatic Filariasis Elimination Program, Ministère de la Santé, Ouagadougou, Burkina Faso
| | - Biholong Benjamin Didier
- National Onchocerciasis and Lymphatic Filariasis Control Program, Ministry of Health, Yaounde, Cameroon
| | - Nko'Ayissi Georges
- National Onchocerciasis and Lymphatic Filariasis Control Program, Ministry of Health, Yaounde, Cameroon
| | - Benjamin Marfo
- Neglected Tropical Diseases Programme, Ghana Health Service, Accra, Ghana
| | | | | | - Eksi Wijayanti
- National Institute Health Research & Development, Ministry of Health, Jakarta, Indonesia
| | - Yaya Ibrahim Coulibaly
- Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Bamako, Mali
| | - Salif Seriba Doumbia
- Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Bamako, Mali
| | - Pradip Rimal
- Epidemiology and Disease Control Division, Department of Health Service, Kathmandu, Nepal
| | | | - Yukaba Bah
- National Neglected Tropical Disease Program, Ministry of Health and Sanitation, Freetown, Sierra Leone
| | - Upendo Mwingira
- Neglected Tropical Disease Control Programme, National Institute for Medical Research, Dar es Salaam, Tanzania
| | - Andreas Nshala
- IMA World Health/Tanzania NTD Control Programme, Uppsala University, & TIBA Fellow, Dar es Salaam, Tanzania
| | - Edridah Muheki
- Programme to Eliminate Lymphatic Filariasis, Ministry of Health, Kampala, Uganda
| | - Joseph Shott
- Division of Neglected Tropical Diseases, Office of Infectious Diseases, Bureau for Global Health, USAID, Washington, DC, United States of America
| | - Violetta Yevstigneyeva
- Division of Neglected Tropical Diseases, Office of Infectious Diseases, Bureau for Global Health, USAID, Washington, DC, United States of America
| | - Egide Ndayishimye
- Global Health, Population, and Nutrition, FHI 360, Washington, DC, United States of America
| | - Margaret Baker
- Global Health Division, RTI International, Washington, DC, United States of America
| | - John Kraemer
- Global Health Division, RTI International, Washington, DC, United States of America
- Georgetown University, Washington, DC, United States of America
| | - Molly Brady
- Global Health Division, RTI International, Washington, DC, United States of America
| |
Collapse
|
2
|
Laing R, Gillan V, Devaney E. Ivermectin - Old Drug, New Tricks? Trends Parasitol 2017; 33:463-472. [PMID: 28285851 PMCID: PMC5446326 DOI: 10.1016/j.pt.2017.02.004] [Citation(s) in RCA: 205] [Impact Index Per Article: 29.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Revised: 02/14/2017] [Accepted: 02/15/2017] [Indexed: 11/30/2022]
Abstract
Ivermectin is one of the most important drugs in veterinary and human medicine for the control of parasitic infection and was the joint focus of the 2015 Nobel Prize in Physiology or Medicine, some 35 years after its remarkable discovery. Although best described for its activity on glutamate-gated chloride channels in parasitic nematodes, understanding of its mode of action remains incomplete. In the field of veterinary medicine, resistance to ivermectin is now widespread, but the mechanisms underlying resistance are unresolved. Here we discuss the history of this versatile drug and its use in global health. Based on recent studies in a variety of systems, we question whether ivermectin could have additional modes of action on parasitic nematodes. Ligand-gated ion channels, particularly glutamate-gated chloride channels, are well characterised as the targets of IVM in nematodes and insects. Nematode genomes are helping to cast light on the diversity of ion-channel subunits in different parasite species of human and veterinary importance. Resistance to IVM is an increasing problem in the control of parasitic nematodes, and resolving the mechanisms is an important research priority. Recent studies in other biological systems suggest that IVM can affect a number of additional pathways. IVM may have novel applications in the treatment and control of important human diseases.
Collapse
Affiliation(s)
- Roz Laing
- Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK.
| | - Victoria Gillan
- Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK
| | - Eileen Devaney
- Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK
| |
Collapse
|
3
|
Wilson NO, Badara Ly A, Cama VA, Cantey PT, Cohn D, Diawara L, Direny A, Fall M, Feeser KR, Fox LM, Kabore A, Seck AF, Sy N, Ndiaye D, Dubray C. Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin. PLoS Negl Trop Dis 2016; 10:e0005198. [PMID: 27926918 PMCID: PMC5142766 DOI: 10.1371/journal.pntd.0005198] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2016] [Accepted: 11/18/2016] [Indexed: 11/19/2022] Open
Abstract
In Africa, onchocerciasis and lymphatic filariasis (LF) are co-endemic in many areas. Current efforts to eliminate both diseases are through ivermectin-based mass drug administration (MDA). Years of ivermectin distribution for onchocerciasis may have interrupted LF transmission in certain areas. The Kédougou region, Senegal, is co-endemic for LF and onchocerciasis. Though MDA for onchocerciasis started in 1988, in 2014 albendazole had not yet been added for LF. The objective of this study was to assess in an integrated manner the LF and onchocerciasis status in the three districts of the Kédougou region after ≥10 years of ivermectin-based MDA. The study employed an African Programme for Onchocerciasis Control (APOC) onchocerciasis-related methodology. In the three districts, 14 villages close to three rivers that have Simulium damnosum breeding sites were surveyed. Convenience sampling of residents ≥5 years old was performed. Assessment for LF antigenemia by immunochromatographic testing (ICT) was added to skin snip microscopy for onchocerciasis. Participants were also tested for antibodies against Wb123 (LF) and Ov16 (onchocerciasis) antigens. In two districts, no participants were ICT or skin snip positive. In the third district, 3.5% were ICT positive and 0.7% were skin snip positive. In all the three districts, Wb123 prevalence was 0.6%. Overall, Ov16 prevalence was 6.9%. Ov16 prevalence among children 5-9 years old in the study was 2.5%. LF antigenemia prevalence was still above treatment threshold in one district despite ≥10 years of ivermectin-based MDA. The presence of Ov16 positive children suggested recent transmission of Onchocerca volvulus. This study showed the feasibility of integrated evaluation of onchocerciasis and LF but development of integrated robust methods for assessing transmission of both LF and onchocerciasis are needed to determine where MDA can be stopped safely in co-endemic areas.
Collapse
Affiliation(s)
- Nana O. Wilson
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America
- * E-mail: (NOW); (CD)
| | | | - Vitaliano A. Cama
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America
| | - Paul T. Cantey
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America
| | - Daniel Cohn
- RTI International, Washington, DC, United States of America
| | - Lamine Diawara
- World Health Organization, Regional Office for Africa, Senegal
- African Programme for Onchocerciasis Control Representative, Ougadougou, Burkina Faso
| | | | | | - Karla R. Feeser
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America
| | - LeAnne M. Fox
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America
| | - Achille Kabore
- RTI International, Washington, DC, United States of America
| | - Amadou F. Seck
- Ministère de la Santé et de l’Action Sociale, Dakar, Senegal
| | - Ngayo Sy
- Service de Lutte Antiparasitaire, Ministère de la Santé et de l’Action Sociale, Thies, Senegal
| | | | - Christine Dubray
- Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America
- * E-mail: (NOW); (CD)
| |
Collapse
|
4
|
Jambulingam P, Subramanian S, de Vlas SJ, Vinubala C, Stolk WA. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators. Parasit Vectors 2016; 9:501. [PMID: 27624157 PMCID: PMC5022201 DOI: 10.1186/s13071-016-1768-y] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Accepted: 08/22/2016] [Indexed: 12/03/2022] Open
Abstract
Background India has made great progress towards the elimination of lymphatic filariasis. By 2015, most endemic districts had completed at least five annual rounds of mass drug administration (MDA). The next challenge is to determine when MDA can be stopped. We performed a simulation study with the individual-based model LYMFASIM to help clarify this. Methods We used a model-variant for Indian settings. We considered different hypotheses on detectability of antigenaemia (Ag) in relation to underlying adult worm burden, choosing the most likely hypothesis by comparing the model predicted association between community-level microfilaraemia (Mf) and antigenaemia (Ag) prevalence levels to observed data (collated from literature). Next, we estimated how long MDA must be continued in order to achieve elimination in different transmission settings and what Mf and Ag prevalence may still remain 1 year after the last required MDA round. The robustness of key-outcomes was assessed in a sensitivity analysis. Results Our model matched observed data qualitatively well when we assumed an Ag detection rate of 50 % for single worm infections, which increases with the number of adult worms (modelled by relating detection to the presence of female worms). The required duration of annual MDA increased with higher baseline endemicity and lower coverage (varying between 2 and 12 rounds), while the remaining residual infection 1 year after the last required treatment declined with transmission intensity. For low and high transmission settings, the median residual infection levels were 1.0 % and 0.4 % (Mf prevalence in the 5+ population), and 3.5 % and 2.0 % (Ag prevalence in 6–7 year-old children). Conclusion To achieve elimination in high transmission settings, MDA must be continued longer and infection levels must be reduced to lower levels than in low-endemic communities. Although our simulations were for Indian settings, qualitatively similar patterns are also expected in other areas. This should be taken into account in decision algorithms to define whether MDA can be interrupted. Transmission assessment surveys should ideally be targeted to communities with the highest pre-control transmission levels, to minimize the risk of programme failure. Electronic supplementary material The online version of this article (doi:10.1186/s13071-016-1768-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Purushothaman Jambulingam
- Vector Control Research Centre (Indian Council of Medical Research), Indira Nagar, Puducherry, 605006, India
| | - Swaminathan Subramanian
- Vector Control Research Centre (Indian Council of Medical Research), Indira Nagar, Puducherry, 605006, India.
| | - S J de Vlas
- Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
| | - Chellasamy Vinubala
- Vector Control Research Centre (Indian Council of Medical Research), Indira Nagar, Puducherry, 605006, India
| | - W A Stolk
- Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
| |
Collapse
|
5
|
Krotneva SP, Coffeng LE, Noma M, Zouré HGM, Bakoné L, Amazigo UV, de Vlas SJ, Stolk WA. African Program for Onchocerciasis Control 1995-2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases. PLoS Negl Trop Dis 2015; 9:e0004051. [PMID: 26401658 PMCID: PMC4581698 DOI: 10.1371/journal.pntd.0004051] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Accepted: 08/12/2015] [Indexed: 12/17/2022] Open
Abstract
Since its initiation in 1995, the African Program for Onchocerciasis Control (APOC) has had a substantial impact on the prevalence and burden of onchocerciasis through annual ivermectin mass treatment. Ivermectin is a broad-spectrum anti-parasitic agent that also has an impact on other co-endemic parasitic infections. In this study, we roughly assessed the additional impact of APOC activities on the burden of the most important off-target infections: soil-transmitted helminthiases (STH; ascariasis, trichuriasis, hookworm, and strongyloidiasis), lymphatic filariasis (LF), and scabies. Based on a literature review, we formulated assumptions about the impact of ivermectin treatment on the disease burden of these off-target infections. Using data on the number of ivermectin treatments in APOC regions and the latest estimates of the burden of disease, we then calculated the impact of APOC activities on off-target infections in terms of disability-adjusted life years (DALYs) averted. We conservatively estimated that between 1995 and 2010, annual ivermectin mass treatment has cumulatively averted about 500 thousand DALYs from co-endemic STH infections, LF, and scabies. This impact comprised approximately an additional 5.5% relative to the total burden averted from onchocerciasis (8.9 million DALYs) and indicates that the overall cost-effectiveness of APOC is even higher than previously reported. Onchocerciasis, or river blindness, is an infectious disease caused by the worm Onchocerca volvulus, which is transmitted between humans through the bites of blackflies and causes deforming skin disease, itch, and vision loss. The African Programme for Onchocerciasis Control (APOC) aims to control morbidity due to onchocerciasis by implementing mass drug administration (MDA) with ivermectin in endemic areas, targeting the whole population except for children under five and pregnant women. Aside from its effect on onchocerciasis, ivermectin also affects other parasitic infections such as lymphatic filariasis, intestinal worm infections, and scabies, which are all significantly co-endemic in areas covered by APOC. In this paper, the researchers roughly estimate the health impact of ivermectin MDA on off-target infections based on the number of dispensed treatments up to 2010, published estimates of the disease burden of off-target infections, and the expected effect of ivermectin treatment on the burden of these infections (based on literature review). This off-target health impact of APOC constitutes about 500 thousand years worth of healthy years of life (an additional 5.5% on top of the impact of APOC on the burden of onchocerciasis) and indicates that the cost-effectiveness of APOC is even higher than previously estimated.
Collapse
Affiliation(s)
- Stanimira P. Krotneva
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Luc E. Coffeng
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
- * E-mail:
| | - Mounkaila Noma
- African Programme for Onchocerciasis Control, Ouagadougou, Burkina Faso
| | | | - Lalle Bakoné
- African Programme for Onchocerciasis Control, Ouagadougou, Burkina Faso
| | | | - Sake J. de Vlas
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Wilma A. Stolk
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| |
Collapse
|
6
|
Cross C, Olamiju F, Richards F, Bush S, Hopkins A, Haddad D. From River Blindness to Neglected Tropical Diseases--Lessons Learned in Africa for Programme Implementation and Expansion by the Non-governmental Partners. PLoS Negl Trop Dis 2015; 9:e0003506. [PMID: 25974037 PMCID: PMC4431851 DOI: 10.1371/journal.pntd.0003506] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Affiliation(s)
| | | | - Frank Richards
- The Carter Center, Atlanta, Georgia, United States of America
| | | | - Adrian Hopkins
- Mectizan Donation Programme, Atlanta, Georgia, United States of America
| | - Danny Haddad
- Emory Global Vision Initiative, Atlanta, Georgia, United States of America
| |
Collapse
|
7
|
Endeshaw T, Taye A, Tadesse Z, Katabarwa MN, Shafi O, Seid T, Richards FO. Presence of Wuchereria bancrofti microfilaremia despite 7 years of annual ivermectin monotherapy mass drug administration for onchocerciasis control: a study in north-west Ethiopia. Pathog Glob Health 2015; 109:344-51. [PMID: 26878935 PMCID: PMC4768627 DOI: 10.1080/20477724.2015.1103501] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
BACKGROUND There is considerable interest in determining whether mass drug administration (MDA) with ivermectin for onchocerciasis control will eliminate coendemic lymphatic filariasis (LF). The objective of this study was to determine the prevalence of LF microfilaremia in onchocerciasis endemic districts that had received 7 years of MDA with ivermectin. METHOD Three villages with a 2010 LF circulating antigenaemia prevalence (determined in a mapping exercise using immunochromatography tests) ranging from 23 to 56% were surveyed for the presence of Wuchereria bancrofti microfilaria (mf) in 2012. These villages had been treated with ivermectin MDA for onchocerciasis with reported total population coverage of ≥65%. A total of 774 residents aged 2 years and above, of both genders, provided 60 μl nocturnal blood samples between 10 pm and 2 am. Standard thick smears were prepared and examined microscopically after Giemsa staining for the presence of W. bancrofti mf. RESULTS The mean mf prevalence was 4.7% (village range 1.1-11.0%). The mean mf density was 9.8 mf/60 μl (village range 9-13.1) among the positive individuals. Children in the 2-4-year-old and 5-9-year-old age groups were infected suggesting transmission occurred during the MDA period. A village level review of MDA treatment coverage records showed an average total population coverage of 66.4% over a 7-year period, but with a considerable range of annual coverage (43.0-89.9%). In addition, village level treatment coverage data were missing from the village with the highest mf prevalence (11%) for 2 of the 7 years. CONCLUSION 7 years of annual mass treatment with ivermectin monotherapy for onchocerciasis did not interrupt LF transmission. In expanding the onchocerciasis ivermectin MDA programme to include LF, albendazole should be added and treatment coverage improved.
Collapse
Affiliation(s)
| | | | | | | | - Oumer Shafi
- National Disease Contro, The Federal Ministry of Health, Addis Ababa, Ethiopia
| | | | | |
Collapse
|
8
|
Impact of three rounds of mass drug administration on lymphatic filariasis in areas previously treated for onchocerciasis in Sierra Leone. PLoS Negl Trop Dis 2013; 7:e2273. [PMID: 23785535 PMCID: PMC3681681 DOI: 10.1371/journal.pntd.0002273] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2012] [Accepted: 05/06/2013] [Indexed: 11/19/2022] Open
Abstract
Background 1974–2005 studies across Sierra Leone showed onchocerciasis endemicity in 12 of 14 health districts (HDs) and baseline studies 2005–2008 showed lymphatic filariasis (LF) endemicity in all 14 HDs. Three integrated annual mass drug administration (MDA) were conducted in the 12 co-endemic districts 2008–2010 with good geographic, programme and drug coverage. Midterm assessment was conducted 2011 to determine impact of these MDAs on LF in these districts. Methodology/Principal Findings The mf prevalence and intensity in the 12 districts were determined using the thick blood film method and results compared with baseline data from 2007–2008. Overall mf prevalence fell from 2.6% (95% CI: 2.3%–3.0%) to 0.3% (95% CI: 0.19%–0.47%), a decrease of 88.5% (p = 0.000); prevalence was 0.0% (100.0% decrease) in four districts: Bo, Moyamba, Kenema and Kono (p = 0.001, 0.025, 0.085 and 0.000 respectively); and seven districts had reductions in mf prevalence of between 70.0% and 95.0% (p = 0.000, 0.060, 0.001, 0.014, 0.000, 0.000 and 0.002 for Bombali, Bonthe, Kailahun, Kambia, Koinadugu, Port Loko and Tonkolili districts respectively). Pujehun had baseline mf prevalence of 0.0%, which was maintained. Only Bombali still had an mf prevalence ≥1.0% (1.58%, 95% CI: 0.80%–3.09%)), and this is the district that had the highest baseline mf prevalence: 6.9% (95% CI: 5.3%–8.8%). Overall arithmetic mean mf density after three MDAs was 17.59 mf/ml (95% CI: 15.64 mf/ml–19.55 mf/ml) among mf positive individuals (65.4% decrease from baseline of 50.9 mf/ml (95% CI: 40.25 mf/ml–61.62 mf/ml; p = 0.001) and 0.05 mf/ml (95% CI: 0.03 mf/ml–0.08 mf/ml) for the entire population examined (96.2% decrease from baseline of 1.32 mf/ml (95% CI: 1.00 mf/ml–1.65 mf/ml; p = 0.000)). Conclusions/Significance The results show that mf prevalence decreased to <1.0% in all but one of the 12 districts after three MDAs. Overall mf density reduced by 65.0% among mf-positive individuals, and 95.8% for the entire population. Onchocerciasis studies across Sierra Leone between 1974 and 2005 showed that 12 of the 14 health districts (HDs) are endemic for onchocerciasis. Baseline lymphatic filariasis (LF) studies 2005–2008 showed that all 14 HDs of Sierra Leone are LF endemic. Three annual rounds of integrated mass drug administration (MDA) with ivermectin and albendazole 2008–2010 were conducted in the 12 HDs that are co-endemic for onchocerciasis and LF with good geographic, epidemiological drug (or programme) and drug coverage. A midterm evaluation study of mf prevalence and density was conducted in the 12 HDs in 2011. The hypothesis proposed for this study is that areas previously exposed to ivermectin treatment for onchocerciasis control may require less rounds of annual MDA to eliminate LF (i.e. reduce microfilaremia (mf) prevalence to <1%). Results of the midterm evaluation study showed very significant and rapid reduction of mf prevalence and density with 11 out of the 12 districts having mf prevalence <1%. Relatively low LF baseline prevalence and effective integrated MDA for onchocerciasis and LF have led to rapid reduction in LF prevalence.
Collapse
|
9
|
Okorie PN, McKenzie FE, Ademowo OG, Bockarie M, Kelly-Hope L. Nigeria Anopheles vector database: an overview of 100 years' research. PLoS One 2011; 6:e28347. [PMID: 22162764 PMCID: PMC3230596 DOI: 10.1371/journal.pone.0028347] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2011] [Accepted: 11/07/2011] [Indexed: 11/19/2022] Open
Abstract
Anopheles mosquitoes are important vectors of malaria and lymphatic filariasis (LF), which are major public health diseases in Nigeria. Malaria is caused by infection with a protozoan parasite of the genus Plasmodium and LF by the parasitic worm Wuchereria bancrofti. Updating our knowledge of the Anopheles species is vital in planning and implementing evidence based vector control programs. To present a comprehensive report on the spatial distribution and composition of these vectors, all published data available were collated into a database. Details recorded for each source were the locality, latitude/longitude, time/period of study, species, abundance, sampling/collection methods, morphological and molecular species identification methods, insecticide resistance status, including evidence of the kdr allele, and P. falciparum sporozoite rate and W. bancrofti microfilaria prevalence. This collation resulted in a total of 110 publications, encompassing 484,747 Anopheles mosquitoes in 632 spatially unique descriptions at 142 georeferenced locations being identified across Nigeria from 1900 to 2010. Overall, the highest number of vector species reported included An. gambiae complex (65.2%), An. funestus complex (17.3%), An. gambiae s.s. (6.5%). An. arabiensis (5.0%) and An. funestus s.s. (2.5%), with the molecular forms An. gambiae M and S identified at 120 locations. A variety of sampling/collection and species identification methods were used with an increase in molecular techniques in recent decades. Insecticide resistance to pyrethroids and organochlorines was found in the main Anopheles species across 45 locations. Presence of P. falciparum and W. bancrofti varied between species with the highest sporozoite rates found in An. gambiae s.s, An. funestus s.s. and An. moucheti, and the highest microfilaria prevalence in An. gambiae s.l., An. arabiensis, and An. gambiae s.s. This comprehensive geo-referenced database provides an essential baseline on Anopheles vectors and will be an important resource for malaria and LF vector control programmes in Nigeria.
Collapse
Affiliation(s)
- Patricia Nkem Okorie
- Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
| | | | | | | | | |
Collapse
|
10
|
Richards FO, Eigege A, Miri ES, Kal A, Umaru J, Pam D, Rakers LJ, Sambo Y, Danboyi J, Ibrahim B, Adelamo SE, Ogah G, Goshit D, Oyenekan OK, Mathieu E, Withers PC, Saka YA, Jiya J, Hopkins DR. Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria. PLoS Negl Trop Dis 2011; 5:e1346. [PMID: 22022627 PMCID: PMC3191131 DOI: 10.1371/journal.pntd.0001346] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2011] [Accepted: 08/22/2011] [Indexed: 11/18/2022] Open
Abstract
The current strategy for interrupting transmission of lymphatic filariasis (LF) is annual mass drug administration (MDA), at good coverage, for 6 or more years. We describe our programmatic experience delivering the MDA combination of ivermectin and albendazole in Plateau and Nasarawa states in central Nigeria, where LF is caused by anopheline transmitted Wuchereria bancrofti. Baseline LF mapping using rapid blood antigen detection tests showed mean local government area (LGA) prevalence of 23% (range 4–62%). MDA was launched in 2000 and by 2003 had been scaled up to full geographic coverage in all 30 LGAs in the two states; over 26 million cumulative directly observed treatments were provided by community drug distributors over the intervention period. Reported treatment coverage for each round was ≥85% of the treatment eligible population of 3.7 million, although a population-based coverage survey in 2003 showed lower coverage (72.2%; 95% CI 65.5–79.0%). To determine impact on transmission, we monitored three LF infection parameters (microfilaremia, antigenemia, and mosquito infection) in 10 sentinel villages (SVs) serially. The last monitoring was done in 2009, when SVs had been treated for 7–10 years. Microfilaremia in 2009 decreased by 83% from baseline (from 4.9% to 0.8%); antigenemia by 67% (from 21.6% to 7.2%); mosquito infection rate (all larval stages) by 86% (from 3.1% to 0.4%); and mosquito infectivity rate (L3 stages) by 76% (from 1.3% to 0.3%). All changes were statistically significant. Results suggest that LF transmission has been interrupted in 5 of the 10 SVs, based on 2009 finding of microfilaremia ≥1% and/or L3 stages in mosquitoes. Four of the five SVs where transmission persists had baseline antigenemia prevalence of >25%. Longer or additional interventions (e.g., more frequent MDA treatments, insecticidal bed nets) should be considered for ‘hot spots’ where transmission is ongoing. Lymphatic filariasis is a mosquito transmitted disease that is best known for causing elephantiasis (grossly swollen legs and genitals). The current strategy for halting lymphatic filariasis in sub Saharan Africa is to establish programs that deliver 6 or more years of annual doses of tablets in community wide treatment programs (called mass drug administration). The tablets are safe, and donated by Merck & Co. and GlaxoSmithKline. We describe a mass drug administration program in central Nigeria that has, since 2000, provided over 23 million cumulative annual treatments to a population of 3.7 million persons. To assess what should be happening generally throughout the program area, lymphatic filariasis infection was monitored in ten ‘sentinel villages.’ In 2009, sentinel village monitoring showed that lymphatic filariasis infection had been reduced between 67–86% compared to levels present when the program began. However, these results were not as good as desired, and suggest that longer or increased efforts are needed beyond 6 years if lymphatic filariasis elimination is to be achieved.
Collapse
Affiliation(s)
| | | | | | | | | | - Davou Pam
- University of Jos, Plateau State, Jos, Nigeria
| | - Lindsay J. Rakers
- The Carter Center, Atlanta, Georgia, United States of America
- * E-mail:
| | | | | | | | | | - Gladys Ogah
- Nasarawa State Ministry of Health, Lafia, Nigeria
| | | | | | - Els Mathieu
- Centers for Disease Control, Atlanta, Georgia, United States of America
| | | | - Yisa A. Saka
- Nigeria Federal Ministry of Health, Abuja, Nigeria
| | | | | |
Collapse
|
11
|
Current evidence on the use of antifilarial agents in the management of bancroftian filariasis. J Trop Med 2010; 2011:175941. [PMID: 21234244 PMCID: PMC3018634 DOI: 10.1155/2011/175941] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2010] [Accepted: 11/29/2010] [Indexed: 11/17/2022] Open
Abstract
Many trials have explored the efficacy of individual drugs and drug combinations to treat bancroftian filariasis. This narrative review summarizes the current evidence for drug management of bancroftian filariasis.
Diethylcarbamazine (DEC) remains the prime antifilarial agent with a well-established microfilaricidal and some macrofilaricidal effects. Ivermectin (IVM) is highly microfilaricidal but minimally macrofilaricidal. The role of albendazole (ALB) in treatment regimens is not well established though the drug has a microfilaricidal effect. The combination of DEC+ALB has a better long-term impact than IVM+ALB. Recent trials have shown that doxycycline therapy against Wolbachia, an endosymbiotic bacterium of the parasite, is capable of reducing microfilaria rates and adult worm activity. Followup studies on mass drug administration (MDA) are yet to show a complete interruption of transmission, though the infection rates are reduced to a very low level.
Collapse
|